How were Eleven Biotherapeutics' earnings last quarter?

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) released its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03.

What other stocks do shareholders of Eleven Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eleven Biotherapeutics investors own include Synergy Pharmaceuticals (SGYP) , Exelixis (EXEL) , Immunomedics (IMMU) , Dynavax Technologies (DVAX) , Sesen Bio (SESN) , iShares Preferred and Income Securities ETF (PFF) and Inovio Pharmaceuticals (INO) .

NASDAQ:EBIO

Eleven Biotherapeutics (EBIO) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free EBIO Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 15.58 million shs
Average Volume: 2.86 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Eleven Biotherapeutics alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Eleven Biotherapeutics Stock (NASDAQ:EBIO)

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

EBIO Stock News Headlines

December 2, 2023 | afr.com

7-Eleven Australia’s family owners sell for $1.71b

November 11, 2023 | mirror.co.uk

Eleven councillors quit Labour Party as Keir Starmer refuses to back Gaza ceasefire

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

August 16, 2023 | foxnews.com

California mayor criticizes Prop 47 after 7-Eleven Sikh employees beat alleged thief

July 31, 2023 | usatoday.com

Free Slurpees? Yes, here's how to get one today and Tuesday, 7-Eleven's 96th birthday

April 9, 2023 | cbsnews.com

Chicago police close in on 7-Eleven robbery suspects in Lawndale

January 27, 2023 | dallasnews.com

A downtown Dallas 7-Eleven that averaged one police call a day has closed

January 26, 2023 | nypost.com

Chef Daniel Humm’s all-vegan menu at Eleven Madison Park blossoms after rough patch

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

January 15, 2023 | abcnews.go.com

7-Eleven adds new bright purple, zero-sugar Slurpee flavor to the mix

January 15, 2023 | foxnews.com

Eleven New Jersey police officers treated for fentanyl exposure during search, 5 suspects arrested

October 14, 2022 | finance.yahoo.com

7-Eleven, Inc. Introduces Limited Time Only Green Apple Flavor to Slurpee Lineup

September 27, 2022 | finance.yahoo.com

Aeglea BioTherapeutics, Inc. (AGLE)

See More Headlines

Receive EBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eleven Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/15/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:EBIO
CUSIP: N/A
CIK: 1485003
Web: www.elevenbio.com
Phone: (617) 444-8550
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Thomas R. Cannell
President, Chief Executive Officer & Director
Monica Forbes
Chief Financial Officer & Treasurer
Jeannick Cizeau
Head of Research
Glen C. MacDonald
Chief Technology Officer
Kirstin N. Anderson
Senior Director-Finance

Key Competitors

View All Competitors

EBIO Stock Analysis - Frequently Asked Questions

How were Eleven Biotherapeutics' earnings last quarter?: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) released its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03.
What other stocks do shareholders of Eleven Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eleven Biotherapeutics investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Immunomedics (IMMU), Dynavax Technologies (DVAX), Sesen Bio (SESN), iShares Preferred and Income Securities ETF (PFF) and Inovio Pharmaceuticals (INO).

This page (NASDAQ:EBIO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Eleven Biotherapeutics (EBIO) Stock Price, News & Analysis

About Eleven Biotherapeutics Stock (NASDAQ:EBIO)

EBIO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

EBIO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info